A New Jersey-based biotech company is finding quite a bit of success so far during Tuesday’s premarket hours after the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

U.S. industrial production declined by 0.1% from the previous month in November compared to a 0.4% drop in October, and versus market estimates of a 0.2% gain. Commodities In commodity news, oil ...

FDA accepts Tonix’s NDA for TNX-102 SL, a non-opioid fibromyalgia treatment. Learn how this potential new drug addresses ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

Tonix Pharma ( (TNXP) ) has provided an announcement.

"On behalf of the board, we congratulate Joe Clabby on his appointment," said Tony Meeker, BBSI's chairman of the board. "Consistent with our board development and succession planning process, we are ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, ...

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted ...